The latest report by IMARC Group, titled “Autoinjector Market Report by Type (Disposable Autoinjectors, Reusable Autoinjectors), Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, and Others), End User (Home Care Settings, Hospitals and Clinics), and Region 2025-2033,” finds that the global autoinjector market reached a value of USD 2.6 Billion in 2024. An autoinjector is a self-injectable device having a pre-charged dosage of drugs. It delivers drugs through the subcutaneous or intramuscular route and offers several advantages, such as dosage accuracy, improved patient compliance, lower needlestick injuries, and enhanced efficiency of healthcare professionals. These devices are widely used during emergency conditions, such as migraine, anaphylaxis, status epilepticus, diabetes, psoriasis, multiple sclerosis, and rheumatoid arthritis. Owing to these properties, autoinjectors find extensive applications in hospitals, clinics, and home care centers across the globe.
Global Autoinjector Market Trends:
The market is primarily driven by the growing prevalence of asthma, arthritis, cancer, chronic obstructive pulmonary disease (COPD), and Alzheimer’s disease. In addition, the implementation of favorable government initiatives to promote the use of autoinjectors in schools represents another major growth-inducing factor. Besides this, key players are investing in research and development (R&D) activities to develop cost-effective and new technology-based autoinjectors for treating rheumatoid arthritis and multiple sclerosis. This, coupled with the rising awareness among individuals about the benefits of autoinjectors, is contributing to market growth. Moreover, the growing adoption of targeted therapies to alter proteins within cancer cells and prevent the formation of blood vessels in the tumor is also creating a favorable market outlook across the globe. Looking forward, IMARC Group expects the market to reach a value of USD 8.2 Billion by 2033, exhibiting a CAGR of 13.19% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Type, Application, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Amgen Inc., Antares Pharma Inc., Becton Dickinson and Company, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Haselmeier GmbH (Sulzer Ltd.), Johnson & Johnson, Mylan N.V. (Viatris Inc.), Novartis AG, SHL Medical AG, Teva Pharmaceutical Industries Ltd. and Ypsomed Holding AG. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800